Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 16/20 | 0.57 |
| ▸ | CSF1R | P07333 | 13/20 | 0.57 |
| ▸ | KDR | P35968 | 12/20 | 0.57 |
| ▸ | FLT3 | P36888 | 4/20 | 0.55 |
| ▸ | MET | P08581 | 5/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | TEK | Q02763 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | AXL | P30530 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2176728 | 0.85 | PDGFRB (0.62) | PDGFRBCSF1RKDRFLT3MET | |
| SCHEMBL2173476 | 0.85 | PDGFRB (0.67) | PDGFRBCSF1RKDRFLT3MET | |
| SCHEMBL5598616 | 0.85 | PDGFRB (0.62) | PDGFRBCSF1RKDRFLT3MET | |
| SCHEMBL2177387 | 0.82 | KDR (0.59) | PDGFRBCSF1RKDRFLT3MET | |
| SCHEMBL5598445 | 0.81 | PDGFRB (0.55) | PDGFRBCSF1RKDRFLT3MET | |
| SCHEMBL2176128 | 0.81 | MET (0.64) | PDGFRBCSF1RKDRFLT3MET | |
| SCHEMBL5598961 | 0.81 | PDGFRB (0.54) | PDGFRBCSF1RKDRFLT3MET | |
| SCHEMBL2175586 | 0.79 | MET (0.57) | PDGFRBCSF1RKDRFLT3MET | |
| SCHEMBL2173153 | 0.79 | SMN1; SMN2 (0.55) | PDGFRBCSF1RKDRFLT3MET | |
| SCHEMBL2173716 | 0.79 | KDR (0.59) | PDGFRBCSF1RKDRFLT3MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | claimed |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | claimed |
| EP-1994025-A1 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | claimed |
| WO-2007099326-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | claimed |
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | disclosed |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076074-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, CCNA1 | PDGFRB 2155/4885CSF1R 818/4885KDR 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.